Hematology, CHU Besançon, Besançon Cedex 25030, France.
Hematol Oncol Clin North Am. 2020 Jun;34(3):613-620. doi: 10.1016/j.hoc.2020.01.012. Epub 2020 Apr 4.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) has to be considered an orphan tumoral disease. BPDCN is a good model concerning the structuring and the organization of a concerted medical program on a nation-based, transnational, or international level. In 2019 in France the diagnosis process for BPDCN was clearly established. Two prospective clinical trials are ongoing. Because of the difficulties in diagnostic procedures and the rarity of the disease it is important that European countries collaborate to build a real European network to ensure the best and equitable medical care to all BPDCN patients.
原始滤泡性树突状细胞肿瘤（BPDCN）被认为是一种孤儿肿瘤疾病。BPDCN 是一个很好的模型，涉及到在国家、跨国或国际层面上构建和组织协调一致的医疗计划。2019 年，法国明确建立了 BPDCN 的诊断流程。目前正在进行两项前瞻性临床试验。由于诊断程序的困难和疾病的罕见性，欧洲各国合作建立一个真正的欧洲网络以确保所有 BPDCN 患者获得最佳和公平的医疗服务非常重要。
